The Comirnaty label warns of increased risks of myocarditis and pericarditis, highest in males 12 through 17.
Postmarketing data with COMIRNATY demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination.
1
The Comirnaty label warns of increased risks of myocarditis and pericarditis, highest in males 12 through 17.